Characteristics of included studies.
| Study | Followup, mo | Intervention/Comparison | Population | Route | Mean Age, yrs; M/F | Primary Outcome | Secondary Outcomes |
|---|---|---|---|---|---|---|---|
| De Boer 200844 | 3 | 100 units Botox® vs placebo | Post-stroke shoulder spasticity | IM | 59; 12/9 | Pain VAS, external rotation | — |
| Kong 200745 | 3 | 500 units Dysport™ vs placebo | Post-stroke shoulder spasticity | IM | 52; n = 17 | Pain VAS | Muscle tone, shoulder abduction |
| Lim 200846 | 3 | 100 units Botox® vs triamcinolone acetonide | Post-stroke shoulder spasticity | IM | 61; 15/14 | Pain NRS, physician global, shoulder ROM | Spasticity, adverse events, arm function |
| Marco 200747 | 6 | TENS + 500 units Dysport™ vs TENS + placebo | Post-stroke shoulder spasticity | IM | 66; 21/8 | Pain VAS | Spasticity, shoulder ROM |
| Yelnik 200748 | 1 | 500 units Dysport™ vs placebo | Post-stroke shoulder spasticity | IM | 54 15/5 | Pain VAS, spasticity, use of analgesics, ROM, spasticity | — |
| Singh 200949 | 1 | 100 units Botox® vs placebo | OA, RA | IA | 71; 35/1 | Pain VAS | Dropout, shoulder disability, global scale, quality of life, adverse events |
VAS: visual analog scale; NRS: numeric rating scale; IM: intramuscular; IA: intraarticular; OA: osteoarthritis; RA: rheumatoid arthritis. ROM: range of motion.